Palvella Therapeutics (PVLA) Profit After Tax (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Profit After Tax data on file, last reported at -$15.8 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 92.28% year-over-year to -$15.8 million in Q1 2026; TTM through Mar 2026 was -$49.3 million, a 111.74% decrease from a year earlier, with the FY2025 full-year figure at -$41.6 million, down 138.81% from the prior year.
• Profit After Tax for Q1 2026 stood at -$15.8 million, down from -$12.7 million in the prior quarter.
• Over the last five years, Profit After Tax for PVLA reached as high as $38.0 million in Q4 2023 and fell as low as -$15.8 million in Q1 2026.
• Historically, Profit After Tax has averaged -$5.3 million across 5 years, with a median of -$8.2 million in 2025.
• Across the five-year window, Profit After Tax jumped 585.41% in 2023 and sank 223.34% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$7.8 million in 2022, then surged by 585.41% to $38.0 million in 2023, then tumbled by 110.41% to -$4.0 million in 2024, then slumped by 222.32% to -$12.7 million in 2025, then dropped by 23.81% to -$15.8 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$15.8 million in Q1 2026, -$12.7 million in Q4 2025, and -$11.3 million in Q3 2025.